JP2016185995A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016185995A5 JP2016185995A5 JP2016153074A JP2016153074A JP2016185995A5 JP 2016185995 A5 JP2016185995 A5 JP 2016185995A5 JP 2016153074 A JP2016153074 A JP 2016153074A JP 2016153074 A JP2016153074 A JP 2016153074A JP 2016185995 A5 JP2016185995 A5 JP 2016185995A5
- Authority
- JP
- Japan
- Prior art keywords
- day
- disease
- compound
- use according
- week
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 201000010099 disease Diseases 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 4
- 208000007848 Alcoholism Diseases 0.000 claims 2
- 208000003870 Drug Overdose Diseases 0.000 claims 2
- 102000003840 Opioid Receptors Human genes 0.000 claims 2
- 108090000137 Opioid Receptors Proteins 0.000 claims 2
- 208000026251 Opioid-Related disease Diseases 0.000 claims 2
- 206010033296 Overdoses Diseases 0.000 claims 2
- 201000007930 alcohol dependence Diseases 0.000 claims 2
- 206010013663 drug dependence Diseases 0.000 claims 2
- 231100000725 drug overdose Toxicity 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 208000020016 psychiatric disease Diseases 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011117 substance-related disease Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16170209P | 2009-03-19 | 2009-03-19 | |
| US61/161,702 | 2009-03-19 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014046328A Division JP2014101388A (ja) | 2009-03-19 | 2014-03-10 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016185995A JP2016185995A (ja) | 2016-10-27 |
| JP2016185995A5 true JP2016185995A5 (OSRAM) | 2016-12-28 |
| JP6362644B2 JP6362644B2 (ja) | 2018-07-25 |
Family
ID=42738186
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500776A Expired - Fee Related JP5555890B2 (ja) | 2009-03-19 | 2009-12-04 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014046328A Pending JP2014101388A (ja) | 2009-03-19 | 2014-03-10 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014097613A Withdrawn JP2014139257A (ja) | 2009-03-19 | 2014-05-09 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2016153074A Expired - Fee Related JP6362644B2 (ja) | 2009-03-19 | 2016-08-03 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
Family Applications Before (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500776A Expired - Fee Related JP5555890B2 (ja) | 2009-03-19 | 2009-12-04 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014046328A Pending JP2014101388A (ja) | 2009-03-19 | 2014-03-10 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
| JP2014097613A Withdrawn JP2014139257A (ja) | 2009-03-19 | 2014-05-09 | 高い経口バイオアベイラビリティを有するモルフィナン誘導体 |
Country Status (6)
| Country | Link |
|---|---|
| US (4) | US20100240691A1 (OSRAM) |
| EP (2) | EP2408303A4 (OSRAM) |
| JP (4) | JP5555890B2 (OSRAM) |
| AU (1) | AU2009342654B2 (OSRAM) |
| CA (1) | CA2754984C (OSRAM) |
| WO (1) | WO2010107457A1 (OSRAM) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2754984C (en) * | 2009-03-19 | 2018-06-26 | Alkermes, Inc. | Morphinan derivatives with high oral bioavailability |
| SMT201900357T1 (it) * | 2009-12-04 | 2019-07-11 | Alkermes Pharma Ireland Ltd | Derivati di morfinano per trattamento di abuso di sostanze stupefacenti |
| SI2608670T1 (sl) | 2010-08-23 | 2019-04-30 | Alkermes Pharma Ireland Limited | Postopki za zdravljenje pridobivanja teže, ki je posledica uporabe antipsihotičnih zdravil |
| AU2012351806C1 (en) | 2011-12-15 | 2016-06-16 | Alkermes Pharma Ireland Limited | Compositions of buprenorphine and mu-opioid receptor antagonists |
| US9211293B2 (en) | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| EP2790703B1 (en) * | 2011-12-15 | 2019-06-12 | Alkermes Pharma Ireland Limited | Samidorphan (alks 33) in combination with opioid agonists |
| US10195191B2 (en) | 2011-12-15 | 2019-02-05 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| EP3003311A2 (en) | 2013-05-24 | 2016-04-13 | Alkermes Pharma Ireland Limited | Methods for treating depressive symptoms |
| NZ631018A (en) | 2013-05-24 | 2017-12-22 | Alkermes Pharma Ireland Ltd | Morphan and morphinan analogues, and methods of use |
| IL318587A (en) | 2018-07-23 | 2025-03-01 | Trevi Therapeutics Inc | Treatment of chronic cough, shortness of breath and wheezing |
| IL294601A (en) | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administration of nalbuphine |
| WO2021178405A1 (en) * | 2020-03-02 | 2021-09-10 | University Of Southern California | Opioid receptor antagonists |
| WO2022101444A1 (en) | 2020-11-12 | 2022-05-19 | Alkermes Pharma Ireland Limited | Immediate release multilayer tablet |
| WO2025038406A1 (en) * | 2023-08-11 | 2025-02-20 | Virginia Commonwealth University | Design, synthesis, and biological evaluation of nitrogen-walk derivatives of nan as mu opioid receptor selective modulators |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3856795A (en) * | 1972-04-25 | 1974-12-24 | American Home Prod | Process for preparation of secondary amines from tertiary amines |
| US3957793A (en) * | 1974-09-20 | 1976-05-18 | Sterling Drug Inc. | Hydroxyiminobenzazocines |
| US4032529A (en) * | 1974-09-20 | 1977-06-28 | Sterling Drug Inc. | Aminomethanobenzazocine intermediates |
| US4127577A (en) * | 1975-11-24 | 1978-11-28 | Sterling Drug Inc. | Aminomethanobenzazocine process |
| US4205171A (en) * | 1976-01-12 | 1980-05-27 | Sterling Drug Inc. | Aminomethanobenzazocines and nitromethanobenzazocines |
| US4464378A (en) * | 1981-04-28 | 1984-08-07 | University Of Kentucky Research Foundation | Method of administering narcotic antagonists and analgesics and novel dosage forms containing same |
| US4649200A (en) * | 1986-05-08 | 1987-03-10 | Regents Of The University Of Minnesota | Substituted pyrroles with opioid receptor activity |
| US5028612A (en) * | 1990-03-22 | 1991-07-02 | Hillel Glover | Method for treating emotional numbness |
| US5258386A (en) * | 1991-06-05 | 1993-11-02 | The United States Of America As Represented By The Secretary Of The Army | (+)-3-substituted-N alkylmorphinans, synthesis and use as anticonvulsant and neuroprotective agents |
| US5607941A (en) * | 1992-06-26 | 1997-03-04 | Boehringer Ingelheim Kg | Useful for treating neurodegenerative diseases |
| US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
| JP2000503019A (ja) * | 1996-01-10 | 2000-03-14 | スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ | 複素環縮合モルフィノイド誘導体（ｉｉ） |
| GB9912411D0 (en) * | 1999-05-28 | 1999-07-28 | Pfizer Ltd | Compounds useful in therapy |
| JP4340437B2 (ja) * | 2000-10-31 | 2009-10-07 | レンセラール ポリテクニック インスティチュート | ８−カルボキサミド−２，６−メタノ−３−ベンズアゾシン |
| EA013261B1 (ru) * | 2004-05-14 | 2010-04-30 | Янссен Фармацевтика, Н.В. | Опиоидные соединения, замещенные карбоксамидогруппой |
| US20060063792A1 (en) * | 2004-09-17 | 2006-03-23 | Adolor Corporation | Substituted morphinans and methods of their use |
| KR101115841B1 (ko) * | 2004-11-05 | 2012-03-09 | 렌슬러 폴리테크닉 인스티튜트 | 4-하이드록시벤조모르판 |
| US20070099947A1 (en) * | 2005-11-03 | 2007-05-03 | Alkermes, Inc. | Methods and compositions for the treatment of brain reward system disorders by combination therapy |
| WO2007089934A2 (en) * | 2006-02-01 | 2007-08-09 | Alkermes, Inc. | Methods of treating alcoholism and alcohol related disorders using combination drug therapy and swellable polymers |
| CA2694497C (en) * | 2007-08-09 | 2016-07-12 | Rensselaer Polytechnic Institute | Quaternary opioid carboxamides |
| CA2754984C (en) * | 2009-03-19 | 2018-06-26 | Alkermes, Inc. | Morphinan derivatives with high oral bioavailability |
| WO2010141666A2 (en) * | 2009-06-04 | 2010-12-09 | The General Hospital Corporation | Modulating endogenous beta-endorphin levels |
| US9211293B2 (en) * | 2011-12-15 | 2015-12-15 | Alkermes Pharma Ireland Limited | Opioid agonist antagonist combinations |
| JP5929635B2 (ja) * | 2012-08-30 | 2016-06-08 | 株式会社デンソー | 多段式横型鍛造装置 |
-
2009
- 2009-12-04 CA CA2754984A patent/CA2754984C/en active Active
- 2009-12-04 WO PCT/US2009/066801 patent/WO2010107457A1/en not_active Ceased
- 2009-12-04 AU AU2009342654A patent/AU2009342654B2/en not_active Ceased
- 2009-12-04 EP EP09842019A patent/EP2408303A4/en not_active Withdrawn
- 2009-12-04 JP JP2012500776A patent/JP5555890B2/ja not_active Expired - Fee Related
- 2009-12-04 EP EP16193161.3A patent/EP3170395A1/en not_active Withdrawn
-
2010
- 2010-03-19 US US12/727,784 patent/US20100240691A1/en not_active Abandoned
-
2014
- 2014-03-10 JP JP2014046328A patent/JP2014101388A/ja active Pending
- 2014-05-09 JP JP2014097613A patent/JP2014139257A/ja not_active Withdrawn
- 2014-10-06 US US14/506,941 patent/US20150094325A1/en not_active Abandoned
-
2016
- 2016-08-03 JP JP2016153074A patent/JP6362644B2/ja not_active Expired - Fee Related
- 2016-11-17 US US15/354,244 patent/US20170112827A1/en not_active Abandoned
-
2020
- 2020-01-10 US US16/739,262 patent/US20200383970A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016185995A5 (OSRAM) | ||
| JP2016106150A5 (OSRAM) | ||
| JP2011068653A5 (OSRAM) | ||
| FI3287124T3 (fi) | Ketamiinin oraalinen annosmuoto | |
| JP2012255026A5 (OSRAM) | ||
| PH12015502134A1 (en) | Mosapride sustained-release preparation for providing pharmacological and clinical effects with once-a-day administration | |
| JP2013522212A5 (OSRAM) | ||
| RU2010133489A (ru) | Применение ингибиторов гамма-секретазы для лечения рака | |
| JP2019517542A5 (OSRAM) | ||
| JP2014533272A5 (OSRAM) | ||
| JP2016515628A5 (OSRAM) | ||
| JP2018513188A5 (OSRAM) | ||
| JP2013541583A5 (OSRAM) | ||
| JP2018530578A5 (OSRAM) | ||
| JP2019530706A5 (OSRAM) | ||
| JP2013516493A5 (OSRAM) | ||
| JP2016527312A5 (ja) | ヒスタミンｈ４受容体を介してもたらされた掻痒状態を治療するための医薬組成物 | |
| JP2018531273A5 (OSRAM) | ||
| JP2012505830A5 (OSRAM) | ||
| JP2016505050A5 (OSRAM) | ||
| JP2014148552A5 (OSRAM) | ||
| JP2018506533A5 (OSRAM) | ||
| JP2017516842A5 (OSRAM) | ||
| JP2014520874A5 (OSRAM) | ||
| JP2014058509A5 (OSRAM) |